{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:48:28Z","timestamp":1790822908052,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019510","name":"Omeros Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1053\/j.ajkd.2024.01.530","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T17:24:22Z","timestamp":1710869062000},"page":"361-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review"],"prefix":"10.1053","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih H.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib3","first-page":"472","article-title":"A\u00a0modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1053\/j.ajkd.2024.01.530_bib4","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa1201356","article-title":"Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin","volume":"366","author":"Valleix","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/art.42664","article-title":"Anakinra-associated systemic amyloidosis","volume":"76","author":"Alehashemi","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.kint.2023.08.020","article-title":"Anakinra-associated renal amyloidosis","volume":"105","author":"Nasr","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2016.09.027","article-title":"Kidney involvement in systemic calcitonin amyloidosis associated with medullary thyroid carcinoma","volume":"69","author":"Koopman","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.micron.2008.10.002","article-title":"Optical properties of amyloid stained by Congo red: history and mechanisms","volume":"40","author":"Howie","year":"2009","journal-title":"Micron"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2016.11.017","article-title":"Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.530_bib11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.humpath.2014.04.016","article-title":"An evaluation of Congo red fluorescence for the diagnosis of amyloidosis","volume":"45","author":"Clement","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1053\/j.ajkd.2024.01.530_bib12","series-title":"Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations","first-page":"187","article-title":"Thioflavin T stain: an easier and more sensitive method for amyloid detection","author":"Picken","year":"2012"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2169\/internalmedicine.7955-21","article-title":"AL-kappa primary amyloidosis with apolipoprotein A-IV deposition","volume":"61","author":"Ishimitsu","year":"2022","journal-title":"Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.530_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/labinvest.3700124","article-title":"Two different types of amyloid deposits--apolipoprotein A-IV and transthyretin--in a patient with systemic amyloidosis","volume":"84","author":"Bergstrom","year":"2004","journal-title":"Lab Invest"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.kint.2021.10.019","article-title":"The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis","volume":"101","author":"Said","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.kint.2022.07.020","article-title":"Clinicopathologic and proteomic characteristics of intratubular cytoplasmic AL amyloidosis","volume":"102","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/modpathol.2017.124","article-title":"Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis","volume":"31","author":"Gibier","year":"2018","journal-title":"Mod Pathol"},{"issue":"16","key":"10.1053\/j.ajkd.2024.01.530_bib20","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2012-03-413682","article-title":"How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ki.2012.414","article-title":"The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5858\/arpa.2020-0018-OA","article-title":"Paraffin immunofluorescence increases light-chain detection in extra-renal light chain amyloidosis and other light-chain-associated diseases","volume":"145","author":"Gibier","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00000478-200606000-00002","article-title":"Immunohistochemical classification of amyloid in surgical pathology revisited","volume":"30","author":"Kebbel","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5858\/2007-131-850-TBOSAT","article-title":"The burden of \u201csticky\u201d amyloid: typing challenges","volume":"131","author":"Picken","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib25","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfh503","article-title":"AL-amyloidosis is underdiagnosed in renal biopsies","volume":"19","author":"Novak","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.kint.2019.05.027","article-title":"The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry","volume":"96","author":"Gonzalez Suarez","year":"2019","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib27","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.humpath.2007.04.013","article-title":"Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response","volume":"38","author":"Verine","year":"2007","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ajkd.2024.01.530_bib29","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2012.108","article-title":"Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib31","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3324\/haematol.2022.281431","article-title":"Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort","volume":"107","author":"Colombat","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.530_bib33","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.ajkd.2024.01.530_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.ajkd.2024.01.530_bib35","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.ajkd.2024.01.530_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.26092","article-title":"Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort","volume":"96","author":"Drosou","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib39","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.01.530_bib40","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"10.1053\/j.ajkd.2024.01.530_bib42","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.530_bib43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib44","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.kint.2017.05.004","article-title":"Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor","volume":"92","author":"Rezk","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2024.01.530_bib45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clml.2017.06.004","article-title":"Primary amyloidosis with renal involvement: outcomes in 77 consecutive patients at a single center","volume":"17","author":"Wong","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.530_bib47","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.530_bib49","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.ajkd.2024.01.530_bib51","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ekir.2016.11.005","article-title":"Renal amyloidosis associated with 5 novel variants in the fibrinogen A alpha chain protein","volume":"2","author":"Rowczenio","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib53","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2024.01.530_bib54","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2010-01-261750","article-title":"Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation","volume":"115","author":"Gillmore","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.ajkd.2024.01.530_bib55","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood-2009-06-223792","article-title":"Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation","volume":"115","author":"Stangou","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13506129.2016.1153465","article-title":"Liver transplant alone without kidney transplant for fibrinogen A\u03b1-chain (AFib) renal amyloidosis","volume":"23","author":"Fix","year":"2016","journal-title":"Amyloid"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/13506129.2022.2072198","article-title":"Lysozyme amyloidosis-a report on a large German cohort and the characterization of a novel amyloidogenic lysozyme gene variant","volume":"29","author":"Anker","year":"2022","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2016090951","article-title":"Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype","volume":"28","author":"Nasr","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.md.0000200467.51816.6d","article-title":"Lysozyme amyloidosis: report of 4 cases and a review of the literature","volume":"85","author":"Granel","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1053\/j.ajkd.2024.01.530_bib60","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1093\/ndt\/14.11.2639","article-title":"Hereditary renal amyloidosis associated with variant lysozyme in a large English family","volume":"14","author":"Gillmore","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2024.01.530_bib61","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/lt.20803","article-title":"Hereditary lysozyme amyloidosis: spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation","volume":"12","author":"Loss","year":"2006","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/gut.38.1.151","article-title":"\u2018Fragile\u2019 liver and massive hepatic haemorrhage due to hereditary amyloidosis","volume":"38","author":"Harrison","year":"1996","journal-title":"Gut"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2796.2011.02470.x","article-title":"Hereditary lysozyme amyloidosis\u2014phenotypic heterogeneity and the role of solid organ transplantation","volume":"272","author":"Sattianayagam","year":"2012","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/13506129.2019.1604336","article-title":"Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis","volume":"26","author":"Schmidt","year":"2019","journal-title":"Amyloid"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib65","first-page":"314","article-title":"Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome","volume":"1","author":"Meretoja","year":"1969","journal-title":"Ann Clin Res"},{"issue":"5","key":"10.1053\/j.ajkd.2024.01.530_bib66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/07853890.2016.1177197","article-title":"Causes of death and life span in Finnish gelsolin amyloidosis","volume":"48","author":"Schmidt","year":"2016","journal-title":"Ann Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/10409238.2012.661401","article-title":"Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention","volume":"47","author":"Solomon","year":"2012","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13506129.2015.1119111","article-title":"Gender differences in the clinical course of Finnish gelsolin amyloidosis","volume":"23","author":"Atula","year":"2016","journal-title":"Amyloid"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib69","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejmg.2016.05.015","article-title":"A\u00a0case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype","volume":"59","author":"Tougaard","year":"2016","journal-title":"Eur J Med Genet"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13506129.2022.2070741","article-title":"The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre","volume":"29","author":"Cohen","year":"2022","journal-title":"Amyloid"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib71","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1681\/ASN.2005040382","article-title":"Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis","volume":"16","author":"Gregorini","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.01.530_bib72","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/j.1600-6143.2006.01507.x","article-title":"Organ transplantation in hereditary apolipoprotein AI amyloidosis","volume":"6","author":"Gillmore","year":"2006","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.kint.2020.03.033","article-title":"New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis","volume":"98","author":"Colombat","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib74","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.transproceed.2020.11.012","article-title":"Hereditary apolipoprotein A-1 amyloidosis with Glu34Lys mutation treated by liver transplantation: a case report","volume":"53","author":"Sagawa","year":"2021","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1523-1755.2003.00047.x","article-title":"Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg","volume":"64","author":"Yazaki","year":"2003","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ekir.2017.07.009","article-title":"Hereditary renal amyloidosis associated with a novel apolipoprotein A-II variant","volume":"2","author":"Prokaeva","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII","volume":"28","author":"Nasr","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.01.530_bib78","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ekir.2018.04.009","article-title":"Apolipoprotein CII amyloidosis associated with p.Lys41Thr mutation","volume":"3","author":"Sethi","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2018.1562442","article-title":"Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant","volume":"26","author":"Liapis","year":"2019","journal-title":"Amyloid"},{"key":"10.1053\/j.ajkd.2024.01.530_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","article-title":"Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states","volume":"7","author":"Urieli-Shoval","year":"2000","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imm.13295","article-title":"The turning away of serum amyloid A biological activities and receptor usage","volume":"163","author":"Abouelasrar","year":"2021","journal-title":"Immunology"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib83","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jcmgh.2021.06.016","article-title":"Serum amyloid A promotes inflammation-associated damage and tumorigenesis in a mouse model of colitis-associated cancer","volume":"12","author":"Davis","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13506129.2011.654294","article-title":"Acute-phase serum amyloid A: perspectives on its physiological and pathological roles","volume":"19","author":"Kisilevsky","year":"2012","journal-title":"Amyloid"},{"issue":"23","key":"10.1053\/j.ajkd.2024.01.530_bib85","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib86","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/13506129809007299","article-title":"SAA1 alleles as risk factors in reactive systemic AA amyloidosis","volume":"5","author":"Booth","year":"1998","journal-title":"Amyloid"},{"issue":"9275","key":"10.1053\/j.ajkd.2024.01.530_bib87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib88","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","article-title":"Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review","volume":"103","author":"Karam","year":"2023","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2024.01.530_bib89","first-page":"75","article-title":"Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"Van der Hilst","year":"2016","journal-title":"Biologics"},{"issue":"24","key":"10.1053\/j.ajkd.2024.01.530_bib90","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2169\/internalmedicine.54.4183","article-title":"Tocilizumab for AA amyloidosis after treatment of multicentric Castleman disease with steroids, chemotherapy and rituximab for over 20 years","volume":"54","author":"Iijima","year":"2015","journal-title":"Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2024.01.530_bib91","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1093\/rheumatology\/keaa211","article-title":"Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever","volume":"59","author":"Ugurlu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib92","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/0929867323666151117121706","article-title":"Colchicine, biologic agents and more for the treatment of familial Mediterranean fever: the old, the new, and the rare","volume":"23","author":"Portincasa","year":"2016","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A\u00a0narrative review of the role of transthyretin in health and disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol Ther"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib94","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib95","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","article-title":"Sex differences in wild-type transthyretin amyloidosis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"11","author":"Campbell","year":"2022","journal-title":"Cardiol Ther"},{"issue":"8","key":"10.1053\/j.ajkd.2024.01.530_bib96","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib97","first-page":"438","article-title":"Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M)","volume":"16","author":"Lobato","year":"2003","journal-title":"J\u00a0Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.01.530_bib98","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/ajhp\/zxab356","article-title":"Pharmacotherapy review: emerging treatment modalities in transthyretin cardiac amyloidosis","volume":"79","author":"Plumadore","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1053\/j.ajkd.2024.01.530_bib102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2021.10.024","article-title":"How the amyloid fibril has unraveled: lessons for nephrology","volume":"101","author":"Leung","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib104","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.kint.2023.11.021","article-title":"Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis","volume":"105","author":"Kmochova","year":"2023","journal-title":"Kidney Int"},{"issue":"17","key":"10.1053\/j.ajkd.2024.01.530_bib105","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.jacc.2017.02.047","article-title":"Apolipoprotein A-IV-associated cardiac amyloidosis","volume":"69","author":"Bois","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.01.530_bib106","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00428-021-03073-x","article-title":"A\u00a0systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis","volume":"479","author":"Murakami","year":"2021","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib107","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib108","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ki.2014.11","article-title":"Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis","volume":"86","author":"Larsen","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjh.14519","article-title":"Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir","volume":"177","author":"Leung","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ajcp\/aqac138","article-title":"Leukocyte chemotactic factor 2 amyloidosis (ALECT2) distribution in a Mexican population","volume":"159","author":"De la Cruz Jasso","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/13506129.2016.1145110","article-title":"Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico","volume":"23","author":"Larsen","year":"2016","journal-title":"Amyloid"},{"key":"10.1053\/j.ajkd.2024.01.530_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2021.107375","article-title":"Clinically occult amyloidosis derived from leukocyte chemotactic factor 2 (ALECT 2) with cardiac involvement complicating renal transplantation: case report and literature review","volume":"55","author":"Eletta","year":"2021","journal-title":"Cardiovasc Pathol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib113","first-page":"241","article-title":"Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis","volume":"33","author":"Rezk","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2024.01.530_bib114","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib115","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2016.29","article-title":"Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib116","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/13506129.2020.1722097","article-title":"Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients","volume":"27","author":"Li","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib117","first-page":"266","article-title":"Mixed leukocyte cell-derived chemotaxin 2 and amyloid A renal amyloidosis in a Kazakh-German patient","volume":"10","author":"Godecke","year":"2017","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib118","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ki.2014.45","article-title":"Alect2 amyloidosis: primum non nocere (first, do no harm)","volume":"86","author":"Picken","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.01.530_bib119","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/j.ajkd.2018.10.016","article-title":"LECT2 amyloidosis in kidney transplantation: a report of 5 cases","volume":"74","author":"Mejia-Vilet","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.01.530_bib120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2020.1738376","article-title":"Renal calcitonin amyloidosis in a patient with disseminated medullary thyroid carcinoma","volume":"27","author":"Tan","year":"2020","journal-title":"Amyloid"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2019.1693359","article-title":"Causes of AA amyloidosis: a systematic review","volume":"27","author":"Brunger","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"10.1053\/j.ajkd.2024.01.530_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.kint.2021.09.007","article-title":"A\u00a0mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis","volume":"101","author":"Sikora","year":"2022","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2024.01.530_bib123","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-1172-5-38","article-title":"The Schnitzler syndrome","volume":"5","author":"Lipsker","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib124","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/13506129.2023.2272556","article-title":"AA amyloidosis in a father and daughter as complication of PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome","volume":"31","author":"Brunger","year":"2024","journal-title":"Amyloid"},{"issue":"1","key":"10.1053\/j.ajkd.2024.01.530_bib125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/13506129.2018.1429391","article-title":"Obesity is a significant susceptibility factor for idiopathic AA amyloidosis","volume":"25","author":"Blank","year":"2018","journal-title":"Amyloid"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624006796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624006796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:33:11Z","timestamp":1724355191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624006796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0272638624006796"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.530","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}